Menu Search
Equities

Bayer AG

1BAYN:MIL

Bayer AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)28.73
  • Today's Change-0.07 / -0.24%
  • Shares traded25.85k
  • 1 Year change-50.71%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in EUR

The one analyst offering a 12 month price target expects Bayer AG share price to rise to 125.00 in the next year from the last price of 28.73.
High335.1%125.00
Med335.1%125.00
Low335.1%125.00

Dividends in EUR

Historical dividend information is not available for Bayer AG.
Div growth (TTM)-95.42%
More ▼

Earnings history & estimates in EUR

On Mar 05, 2024, Bayer AG reported 4th quarter 2023 earnings of 1.85 per share. This result exceeded the 1.42 consensus of the 4 analysts covering the companyand exceeded last year's 4th quarter results by 37.04%.
The next earnings announcement is expected on May 14, 2024.
Average growth rate+94.47%
Bayer AG reported annual 2023 earnings of 6.39 per share on Mar 05, 2024.
Average growth rate+1.04%
More ▼

Revenue history & estimates in EUR

-32768 had 4th quarter 2023 revenues of 11.86bn. This missed the 11.89bn consensus estimate of the 4 analysts following the company. This was 18.97% below the prior year's 4th quarter results.
Average growth rate+1.25%
-32768 had revenues for the full year 2023 of 47.64bn. This was 6.11% below the prior year's results.
Average growth rate+2.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.